|
|
Blood, 1 June 2007, Vol. 109, No. 11, pp. 4907-4913.
Prepublished online as a Blood First Edition Paper on February 22, 2007; DOI 10.1182/blood-2006-10-051847.
 Previous Article | Next Article 
Submitted October 12, 2006
Accepted February 11, 2007
Endogenous bcl-2 is not required for the development of Eµ-myc-induced B cell lymphoma
Priscilla N Kelly, Hamsa Puthalakath, Jerry M Adams, and Andreas Strasser*
Department of Medical Biology, The University of Melbourne, Melbourne, Australia
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
* Corresponding author; email: strasser{at}wehi.edu.au.
Although myc and bcl-2 synergize in tumor development, particularly lymphomagenesis, it is not known whether endogenous bcl-2 is required for myc-induced tumorigenesis. To investigate the role of endogenous Bcl-2 in myc-induced lymphomagenesis, we bypassed the early death of Bcl-2-deficient mice by reconstituting lethally irradiated wt mice with a hematopoietic system from fetal liver-derived stem cells of Eµ-myc/bcl-2-/- or control Eµ-myc transgenic embryos. In pre-malignant (healthy) recipients, loss of Bcl-2 caused a moderate decrease in pre-B and immature B cells, and a dramatic reduction of mature B lymphocytes expressing the Eµ-myc transgene. Furthermore, cultured pre-neoplastic Eµ-myc/bcl-2-/- mature B cells displayed accelerated apoptosis compared to Eµ-myc B cells. However, despite the striking reduction in B cell numbers in vivo, ablation of endogenous Bcl-2 did not prevent or even delay development of Eµ-myc lymphoma. Moribund mice presented with similar degrees of splenomegaly, blood leukocyte numbers and tumor dissemination at sacrifice. These findings demonstrate that the initiation, development, continued growth and severity of Eµ-myc lymphoma do not depend upon endogenous Bcl-2, nor upon the total number of B lymphoid cells driven by the Eµ-myc transgene. These results have implications for the treatment of hematopoietic tumors, particularly those that are not caused by Bcl-2 overexpression.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J.M Adams, P.N. Kelly, A. Dakic, S. Carotta, S.L. Nutt, and A. Strasser
Role of "Cancer Stem Cells" and Cell Survival in Tumor Development and Maintenance
Cold Spring Harb Symp Quant Biol,
November 6, 2008;
(2008)
sqb.2008.73.004v1.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Mori, R. E. Rempel, J. T. Chang, G. Yao, A. S. Lagoo, A. Potti, A. Bild, and J. R. Nevins
Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the E{micro}-myc Model and Human Diffuse Large B-Cell Lymphoma
Cancer Res.,
October 15, 2008;
68(20):
8525 - 8534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Newbold, R. K. Lindemann, L. A. Cluse, K. F. Whitecross, A. E. Dear, and R. W. Johnstone
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1066 - 1079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hanahan, E. F. Wagner, and R. D. Palmiter
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer
Genes & Dev.,
September 15, 2007;
21(18):
2258 - 2270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
